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ABSTRACT 
Alzheimer’s disease amyloid-ß (Aß) oligomers are synaptotoxic, inappropriately increasing 
extracellular glutamate concentration and glutamate receptor activation to thereby rapidly 
disrupt synaptic plasticity. Thus, acutely promoting brain glutamate homeostasis with a 
blood-based scavenging system, glutamate-oxaloacetate transaminase (GOT), and blocking 
metabotropic glutamate 5 (mGlu5) receptor or its co-receptor cellular prion protein (PrP), 
prevent the acute inhibition of long-term potentiation (LTP) by exogenous Aß. Here, we 
evaluated the time course of the effects of such interventions in the persistent disruptive 
effects of Aß oligomers, either exogenously injected in wild type rats or endogenously 
generated in transgenic rats that model Alzheimer’s disease amyloidosis. We report that 
repeated, but not acute, systemic administration of recombinant GOT type 1, with or without 
the glutamate co-substrate oxaloacetate, reversed the persistent deleterious effect of 
exogenous Aß on synaptic plasticity. Moreover, similar repetitive treatment reversibly 
abrogated the inhibition of LTP monitored longitudinally in freely behaving transgenic rats. 
Remarkably, brief repeated treatment with an mGlu5 receptor antagonist, basimglurant, or an 
antibody that prevents Aß oligomer binding to PrP, ICSM35, also had similar reversible 
ameliorative effects in the transgenic rat model. Overall, the present findings support the 
ongoing development of therapeutics for early Alzheimer’s disease based on these 
complementary approaches. 
Keywords: Alzheimer’s disease; long-term potentiation; glutamate-oxalate transaminase; 
metabotropic glutamate receptor 5, APP transgenic rat.  
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1. Introduction 
The, albeit relatively limited, clinical effectiveness of the NMDA receptor antagonist 
memantine in the treatment of Alzheimer’s disease strongly supports the search for 
alternative glutamate-based therapeutic strategies (Deardorff and Grossberg, 2016). 
Consistent with a key role for glutamate-mediated synaptotoxic mechanisms, postmortem 
glutamatergic synaptic loss is a very strong morphological correlate of cognitive impairment 
in Alzheimer’s disease (Davies et al., 1987; DeKosky and Scheff, 1990; Overk and Masliah, 
2014; Terry et al., 1991). Indeed, there is now convincing evidence for a causal role for 
amyloid-ß (Aß) at the early stages of Alzheimer’s disease and oligomeric Aß, which is a 
potent synaptotoxin, associates with disease (Bilousova et al., 2016; Cohen et al., 2015; 
Dohler et al., 2014; Lesne et al., 2013; Mc Donald et al., 2010). 
In animal models of Alzheimer’s disease amyloidosis there is growing evidence of 
functional glutamate overload and disruption of glutamate homeostasis (Rudy et al., 2015). 
The disturbance is likely caused by a combination of factors including excessive release of 
glutamate from glial cells and disinhibited neurons, impaired glutamate clearance by loss of 
functional glutamate transporters, and distorted glutamate receptor trafficking (Matos et al., 
2008; Mucke and Selkoe, 2012; Renner et al., 2010; Talantova et al., 2013; Ulrich, 2015). 
Although blocking certain NMDA receptors has beneficial effects in many models, the 
deleterious and dose-limiting side effects of NMDA receptor antagonists are well 
documented (De Felice et al., 2007; Ronicke et al., 2011; Zadori et al., 2014). There is 
growing evidence of the potential superiority of targeting metabotropic glutamate rather than 
NMDA receptors, in particular antagonists selective for subtype 5 (mGlu5) (Haas et al., 
2016; Hamilton et al., 2014; Hamilton et al., 2016; Lauren et al., 2009; Um et al., 2013; Viola 
and Klein, 2015). Importantly, some of these antagonists have been tested in humans, 
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displaying an apparently good safety profile (Berry-Kravis et al., 2016; Reilmann et al., 2015; 
Scharf et al., 2015; Tison et al., 2016). 
Antagonists at the mGlu5 receptor not only block potential adverse effects of Aß-
triggered excess glutamate but also prevent Aß oligomer-mediated aberrant mGlu5 receptor 
trafficking (Renner et al., 2010) and coupling to downstream effectors via binding to cellular 
prion protein (PrP) (Beraldo et al., 2016; Haas et al., 2016; Hamilton et al., 2015; Lauren et 
al., 2009; Um et al., 2013). Indeed, PrP is a receptor for certain synaptotoxic Aß oligomers 
and blocking the binding of Aß oligomers to PrP is also a potentially attractive option (Chung 
et al., 2010; Jarosz-Griffiths et al., 2016; Resenberger et al., 2011). 
Alternative strategies being investigated to counter glutamate dyshomeostasis in 
Alzheimer’s disease include agents that increase glutamate removal from the interstitial fluid 
in the brain directly by inducing glutamate transporters, or indirectly by increasing the 
metabolism of glutamate (Takahashi et al., 2015; Zhang et al., 2016).  
Plasticity at glutamatergic synapses is extremely sensitive to disturbance by 
endogenously generated and exogenously applied synaptotoxic soluble Aß species (Cullen et 
al., 1997; Lambert et al., 1998; Randall et al., 2010; Shankar et al., 2008; Walsh et al., 2002), 
at least partly through mechanisms involving glutamate dyshomeostasis (Lei et al., 2015; Li 
et al., 2009). Previous studies of the acute effects of enzyme-mediated glutamate scavenger 
systems have shown potential beneficial effects against the acute plasticity disrupting effects 
of exogenously applied Aß both in vitro and in vivo (Li et al., 2009; Varga et al., 2015; Zhang 
et al., 2016). In the latter case a blood-based scavenger system consisting of glutamate 
oxaloacetate transaminase (GOT) with oxaloacetate (OXA) was found to transiently abrogate 
synthetic Aß and Alzheimer’s disease brain Aß-mediated inhibition of long-term potentiation 
(LTP) in acutely anaesthetized rats. By increasing the conversion of glutamate in blood to α-
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ketoglutarate, the efflux of excessive glutamate in brain is accelerated (Campos et al., 2011b; 
Castillo et al., 2016; Zlotnik et al., 2007). 
Similar to agents that lower extracellular glutamate concentration in the brain, antagonists 
at glutamate receptors can prevent the acute disruption of synaptic plasticity by exogenously 
applied Aß (Hu et al., 2008; Li et al., 2009; Rammes et al., 2011; Wang et al., 2004). In 
particular, the mGlu5 receptor may be critical for both inhibition of LTP and facilitation of 
long-term depression (LTD) (Hu et al., 2014; Li et al., 2009; Ronicke et al., 2011; Wang et 
al., 2004). Furthermore, consistent with findings that cellular PrP acts as a co-receptor for 
mGlu5 receptors, blocking Aß binding to PrP prevents the acute disruption of synaptic 
plasticity by Aß (Barry et al., 2011; Freir et al., 2011; Hu et al., 2014; Klyubin et al., 
2014a; Lauren et al., 2009; Nicoll et al., 2013) 
Here we directly compare the time course and efficacy of blood based glutamate 
scavengers, mGlu5 receptor antagonists and an antibody preventing Aß binding to PrP, to 
ameliorate Aß-mediated persistent disruption of synaptic plasticity in vivo. We examined the 
persistent inhibition of LTP caused by either exogenous i.c.v. application of a synthetic Aß1-
42 oligomer-enriched preparation or endogenous Aß in a very complete APP-based 
transgenic (TG) rat model of amyloidosis (Leon et al., 2010). In longitudinal studies in 
freely behaving TG rats the reversal of the synaptic plasticity deficits caused by repeated 
treatment with these agents was monitored in individual animals. 
2.  Material and Methods 
2.1 Animals and surgery 
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Rats were housed under a 12 h light-dark cycle at room temperature (19-22 °C). The animal 
care and experimental protocol were approved by the Department of Health, Republic of 
Ireland and the Irish Health Products Regulatory Authority in accordance with EU law.  
The effects of Aß were studied in adult (250-350 g, 8-13 weeks old) male Wistar and 
Lister Hooded rats. In order to record synaptic transmission the surgical and 
electrophysiological methods were similar to those used previously (Hu et al., 2014). For 
electrophysiolgical recording anaesthesia was induced and maintained with urethane (1.5-1.6 
g/kg, i.p.). Monopolar recording electrodes (75 µm inner core diameter, 112 µm external 
diameter) (3.4 mm posterior to bregma and 2.5 mm lateral to midline) and twisted bipolar 
stimulating electrodes (50 µm inner core diameter, 75 µm external diameter) (4.2 mm 
posterior to bregma and 3.8 mm lateral to midline) were constructed from Teflon coated 
tungsten wires. Field excitatory postsynaptic potentials (fEPSPs) were recorded from the 
stratum radiatum in the CA1 area of the dorsal hippocampus in response to stimulation of the 
ipsilateral Schaffer collateral-commissural pathway. The final placement of electrodes was 
optimized by using electrophysiological criteria and confirmed via post-mortem analysis. 
In order to inject Aß or antibody into the brain, a stainless-steel cannula (22 gauge, 0.7 
mm outer diameter) was implanted ipsilaterally above the right lateral ventricle (1 mm lateral 
to the midline and 4 mm below the surface of the dura). The solution was injected 
intracerebroventricularly (i.c.v.) via an internal cannula (28 gauge, 0.36 mm outer diameter) 
at a rate of 1-2 µl per min with a Hamilton syringe (Reno, Nevada, USA). For Aß injection 
the cannula was temporarily implanted under recovery anaesthesia using a mixture of 
ketamine and xylazine (80 and 8 mg/kg, respectively, i.p.). Following the i.c.v. injection of 
Aß or vehicle the guide cannula was removed. The day of i.c.v. injection was termed day 0, 
following which, these animals were housed individually in their home cages. Seven to 
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fourteen days later, the animals were implanted and recorded under non-recovery anesthesia, 
as described above.  
In the studies of synaptic plasticity disruptive effects of endogenous Aß adult male TG 
rats expressing human APP751 with Swedish and Indiana mutations under the control of the 
murine Thy1.2 promoter (McGill-R-Thy1-APP) (Iulita et al., 2014; Leon et al., 2010) and 
their age-matched wild type (WT) littermates were studied. The TG animals were genotyped 
as outlined in (Qi et al., 2014) and ages varied from 3 to 13 months old.  
For the chronic recording the implantation procedure was carried out under anaesthesia 
using a mixture of ketamine (80 mg/kg) and xylazine (8 mg/kg) (both i.p.) according to 
methods similar to those described previously and is comparable to that described above (Li 
et al., 2003). The recording site was located 3.8 mm posterior to bregma and 2.5 mm lateral 
to midline, and the stimulating site was located 4.6 mm posterior to bregma and 3.8 mm 
lateral to midline. All chronically implanted animals also had a cannula inserted over the 
lateral ventricle, as described above. These rats were allowed at least 14 days after surgery 
before recordings began and were housed individually in their home cages between recording 
sessions. 
2.2 Stimulation and recording 
Test EPSPs were evoked by square wave pulses (0.2 ms duration) at a frequency of 0.033 Hz 
and an intensity that triggered a 50% maximum response as determined after constructing an 
input/output curve. Baseline synaptic transmission was recorded for at least 30 min.  In some 
experiments paired-pulse stimulation was applied using a 40 ms inter-pulse interval. 
Awake recordings in the recovery animals were carried out in a well-lit room. The 
recording compartment consisted of the base of the home cage, including normal bedding and 
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food/water, but the sides were replaced with a translucent Perspex plastic box (27× 22× 30 
cm) with an open roof. The rats had access to food and water throughout the whole recording 
session from the same position as in the home cage. All animals were first habituated to the 
recording procedure over the post-surgery recovery period. 
LTP was induced using 200 Hz high frequency stimulation (HFS) consisting of 10 trains 
of 20 stimuli with an inter-train interval of 2 s. A single series was used in the awake rat 
recordings whereas, apart from in Fig. 1, three sets (inter-set interval 5 min) were applied in 
the anaesthetized rats. The stimulation intensity was not changed during HFS.  
2.3 Preparation of synthetic Aß-derived diffusible ligands (ADDLs) 
An Aß solution enriched with oligomers including protofibrils (ADDLs) was prepared using 
synthetic Aß1-42. Aβ1–42 was synthesized and purified by the ERI Amyloid laboratory 
Oxford, CT, USA. Two slightly different methods were used. For the electrophysiology 
experiments, as described previously (Hu et al., 2014), a 1 mM solution of Aß1–42 was 
prepared in hexafluoroisopropanol and incubated at 37 °C for 1 h and briefly vortexed every 
10 min. The hexafluoroisopropanol was evaporated using a speedvac and the dried peptide 
film stored overnight over desiccant at −20 °C. A peptide solution of 22.5 mg/ml was then 
prepared in anhydrous dimethylsulfoxide (DMSO) and subsequently diluted 1:50 with Hams 
F-12 media. After incubation at 4 °C for ~14 h the solution was centrifuged at 16,000×g for 
10 min. The supernatant was recovered and absorbance at 275 nm recorded. The 
concentration of oligomeric Aß was determined using size exclusion chromatography. 
Aliquots of ADDLs were frozen on dry ice and stored at −80 °C until needed. For 
standardizing the DELFIA (dissociation-enhanced lanthanide fluorescence immunoassay), 
~25 mg peptide was dissolved in 2% w/v anhydrous DMSO and gently rocked for ~ 5 
minutes, then diluted to 0.5 mg/ml in phenol red-free Ham’s F12 medium without L-
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glutamine (Caisson Labs) and incubated quiescently at room temperature. Aggregation was 
monitored using asymmetric field flow fractionation. Aβ oligomer formation was judged to 
be complete when <20% of the injected mass eluted as monomer, typically after 24 - 36 h 
incubation. The ADDLs were further assessed by negative-stain electron microscopy. 
Depending on the batch of ADDLs, the amount injected was either 480 or 585 pmol (in 5-12 
µl). 
2.4 Drugs and chemicals  
Oxaloacetate was purchased from Sigma-Aldrich, Wicklow, Ireland. The oxaloacetate 
dose chosen (35 mg/kg in 1 ml, i.v.) was based on previous research (Perez-Mato et al., 
2014). The dose of recombinant glutamate-oxaloacetate transaminase type 1 (rGOT) 
(Megazyme, Bray, Ireland) given (0.39 mg/rat i.v.) was previously reported to significantly 
increase GOT serum concentration for over 20 h (Ruban et al., 2015). Treatment (s.c.) with 
rGOT started immediately after i.c.v. Aß using a dose of 0.39 mg/rat, followed by a 
maintenance dose of 0.13 mg/rat/day to day 6 at 24 h intervals. 
In the awake animal recordings, the co-administration of OXA (35mg/kg) and rGOT 
(0.39 mg/rat) or vehicle (saline, 1 ml) was given i.v. via tail vein to TG rats and WT 
littermates under transient recovery anaethesia (2% isoflurane). After full recovery, the rats 
were transported to the recording cage and then recording was initiated. How was rGOT 
given? 
Basimglurant and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-
imidazol-4-yl)ethynyl)pyridine (CTEP) (both DC chemicals, Shanghai, China), were initially 
dissolved in 10% DMSO (Sigma, Dorset, UK), and administered as a suspension in corn oil 
(volume 0.3-0.4 ml) vehicle. A dose of 2 or 3 mg/kg i.p. was chosen to obtain high mGlu5 
receptor occupation (Jaeschke et al., 2015; Lindemann et al., 2011; Lindemann et al., 2015). 
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For repeated dosing we chose a 3 day schedule, which had proven effective in preventing 
LTP deficits in the APP transgenic rats using different anti-Aß interventions (Qi et al., 2014). 
In preliminary studies a lower dose of 0.4 mg/kg (twice over 3 days, i.p.) failed to 
significantly reverse the LTP deficit (n=3; data not shown). Because of their different half-
lives basimglurant was injected once daily whereas CTEP was administered twice, on day 1 
and 3. The last injection was 2 h before application of HFS. 
The anti-PrP antibody ICSM35 and isotope control antibody BRIC126 were stored as 
stock solutions of 6mg/ml in phosphate-buffered saline (PBS). Injections (10 µl over 3-5 
min) were made via a Hamilton syringe connected to the internal cannula. Based on pilot 
studies and our previous studies (Qi et al., 2014) of the effect of the anti-Aß monoclonal 
antibody McSA1, we chose a protocol of 5 injections of 60 µg, over 3 days, the 5th injection 
being carried out at 2 h before application of HFS. 
2.5 Homogenisation of rat brain tissue for Aß oligomer DELFIA 
Hemi-brains from TG and WT rats varying in age from 3-13 months were frozen at -80 oC 
until needed for Aß oligomer ELISA. All of the genotypes of the rat brain hemispheres were 
anonymized, and then homogenized using a Precellys-24 Ribolyser in Dulbecco’s PBS 
containing Roche Complete protease inhibitor to a final concentration of 10% (w/v). The 
homogenates were assayed for total protein concentration using the Bradford assay by two 
different users until a percentage coefficient of variation less than 10% per sample between 
users was obtained. The homogenates were aliquoted into single thaw volumes in low 
binding eppendorfs (Fisher Scientific). 
2.6 Detection of Aβ oligomers using the anti-Aβ oligomer antibody 1C22 
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The anti-Aβ oligomer antibody 1C22 is a monoclonal murine antibody that binds strongly to 
Aβ oligomers but only weakly to Aβ monomers (Yang et al., 2015). 1C22 (30 µl at 23 µg/ml 
in 10 mM sodium carbonate, pH 9.6) was immobilised on a Lumitrac high binding 384 well 
plate (Greiner Bio-one #781074). The plate was incubated at 400 rpm for 1 h at 37 °C then 
washed. All washes were performed with three 100 µl per well washes of PBS (0.05% 
Tween-20). The plate was blocked with 100 µl per well Superblock (Thermo Scientific) with 
shaking at 400 rpm at 37 °C for 2 h and washed. The rat brain homogenates were defrosted, 
benzonase treated, and diluted in Dulbecco’s PBS to give equivalent total protein 
concentrations (as assessed by the Bradford assay). Additionally, a serial dilution of synthetic 
ADDLs was prepared in age-matched wild-type rat brain homogenate to produce the standard 
curve for each experiment. Aliquots of 30 µl of brain homogenates and standards were 
incubated in the plate for 1 h at 25 °C with shaking at 400 rpm followed by a plate wash. Aβ 
was detected by 30 µl of 0.2 µg/ml biotinylated 82E1 in DELFIA assay buffer (PerkinElmer) 
for 1 h at 25 °C with shaking at 400 rpm.  The plate was washed then incubated for 1 h at 25 
°C with shaking at 400 rpm with 333 ng/ml of DELFIA Eu-N1 streptavidin antibody in 
DELFIA assay buffer (PerkinElmer), washed before enhancing with 80 µl of DELFIA 
Enhancement Solution (PerkinElmer) for 10 min. Plates were scanned for time-resolved 
fluorescence intensity of the europium probe (ʎex 320 nm, ʎem 615 nm) using a PerkinElmer 
EnVision plate reader. All samples were run in quadruplicate.  
The standard curve obtained from the serial dilution of ADDLs was used to convert the 
time resolved fluorescence intensity of each of the brain homogenates into the concentration 
of Aβ oligomers. The standard curve was also used to determine the lower limit of 
quantification (LLOQ) defined as the lowest standard with a percentage backfit of 100±20% 
and a percentage coefficient of variation of <20% and over 9 times the standard deviations of 
negative blank signal. 
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2.7 Serum glutamate assay 
Blood samples were collected in test tubes, centrifuged at 600×g for 10 min, serum was 
removed and immediately frozen and stored at –80 °C. Serum glutamate concentration was 
determined by means of a glutamate assay kit (Cat. No. MAK004, Sigma-Aldrich, Wicklow, 
Ireland) following the manufacturer’s technical instructions.  
2.8 Statistical analysis 
The strength of synaptic transmission is expressed as a percentage of the baseline fEPSP 
amplitude recorded over at least a 30 min period. The magnitude of LTP was measured at 3 h 
post-HFS and expressed as the mean ± SEM % baseline. No data were excluded. Control 
experiments were interleaved randomly throughout experimental sets. Sample sizes including 
animal numbers were chosen to ensure adequate statistical power comparable to previously 
published papers. Data distribution of experiments was assumed to be normal. For statistical 
analysis and graphical display EPSP amplitude was grouped into 10 min epochs. One-way 
ANOVA followed by Bonferroni’s multiple comparison test was used to compare the 
magnitude of LTP between multiple groups; paired and unpaired Student’s t-tests were used 
to compare within and between groups, respectively. Serum glutamate concentration is 
expressed as the mean ± SEM and analysed statistically in a similar manner. The levels of Aß 
oligomers in TG rats were assessed by Fisher’s exact test and Pearson’s r. A p value of <0.05 
was considered statistically significant. 
3. Results 
3.1. Acute treatment with blood-based glutamate scavengers fails to reverse synthetic Aß-
mediated persistent disruption of synaptic plasticity recorded in anaesthetized rats 
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The ability of the peripherally acting glutamate scavenger oxaloacetate to reverse the 
synaptic plasticity disrupting action of Aß was first tested in a delayed model. Previously, 
soluble extract of Alzheimer’s disease brain that contains Aß was reported to persistently 
inhibit LTP, without significantly affecting baseline synaptic transmission, after a single i.c.v. 
injection (Klyubin et al., 2014b). Here, an ADDL preparation of synthetic Aß1-42 (i.c.v.) was 
injected under recovery anaesthesia and the ability to induce LTP was determined 7-9 or 14 d 
later under non-recovery anaesthesia. Whereas the application of HFS failed to induce LTP in 
the animals tested on d 7-9 (Aß7, 107.4±5.4%, mean ± SEM% pre-injection baseline EPSP 
amplitude at 3 h post-HFS, n=8; p<0.05 compared with 132.6±4.8% in controls, n=8, 
ANOVA followed by Bonferroni test), in animals injected i.c.v. with Aß 14 d previously the 
magnitude of LTP was comparable to control levels (Aß14, 131.6±3.5; p>0.05) (Fig. 1A, B). 
The inhibition of LTP appeared to be relatively selective since there was no significant effect 
of Aß injection on baseline excitatory transmission as measured by the amplitude of the 
fEPSP (maximum fEPSP amplitude: vehicle group, 4.7±0.5 mV; Aß7 group, 4.4±0.5 mV; 
Aß14 group, 5.3±0.5 mV; p>0.05), and short-term plasticity as measured by the level of 
paired-pulse facilitation at a 40 ms inter-pulse interval (paired-pulse ratio: vehicle group, 
1.49±0.06; Aß7 group, 1.64±0.18; Aß14 group, 1.49±0.07; p>0.05) (Fig. 1C, D). 
 Initially we studied the effect of oxaloacetate using a single bolus injection of a dose (35 
mg/kg, i.v.) that previously has been reported to reduce free blood and brain glutamate 
concentration (Campos et al., 2011b; Perez-Mato et al., 2014). We previously reported that 
this intervention fully prevented the acute disruption of hippocampal synaptic plasticity 
caused by Aß and reduced blood glutamate concentration by ~30-50% when measured 30 
min and 1 h after injection (Zhang et al., 2016). In the present studies, however, the delayed 
LTP inhibition by Aß  injection 7 d previously was not significantly affected by a single i.v. 
injection of oxaloacetate under non-recovery anaesthesia. Similar to above, in the Aß group 
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that received an i.v. injection of saline vehicle, the application of HFS failed to induce LTP 
(106.1±6.7%, n=6; p<0.05 compared with 137.6±2.1% in controls that received i.c.v. and i.v. 
vehicle injections, n=5, ANOVA followed by Bonferroni test) (Fig. 2A, D). Moreover Aß 
also blocked LTP in animals that received an i.v. injection of oxaloacetate either 20 min or 1 
h before the application of HFS (20 min pre-injection: 110.6±4.0%, n=5 data not shown; 
p>0.05 compared with 106.1±6.7%, n=6 in Aß+vehicle,; 1 h pre-injection: 116.8±4.6%, n=5; 
p>0.05 compared with 109.7±5.5, n=5, in animals that received Aß followed by vehicle) (Fig. 
2B,E).  
Next we attempted to enhance the blood-scavenging effect of oxaloacetate by increasing 
the blood concentration of GOT using recombinant protein type 1 (rGOT) (Perez-Mato et al., 
2014; Ruban et al., 2015; Zlotnik et al., 2007). We previously reported that co-treatment with 
rGOT (0.39 mg/rat) prolonged the oxaloacetate-mediated reduction in serum glutamate 
clearance and the abrogation of the acute deleterious effect of Aß on LTP (Zhang et al., 
2016). However, in animals that received Aß (i.c.v.) 7 d previously, neither rGOT alone nor 
the co-administration of rGOT and oxaloacetate reversed the delayed disruption of LTP when 
applied 1 h prior to the HFS (117.0±1.4, n=5 and 108.0±6.0%, n=5 respectively; p>0.05 
compared with pre-HFS baseline or compared with Aß+vehicle) (Fig. 2B,C,E).   
3.2. Repeated systemic treatment with blood-based glutamate scavengers reverse synthetic 
Aß-mediated persistent disruption of synaptic plasticity  
We hypothesized that the apparent lack of efficacy of acute treatment with the blood 
glutamate scavenging interventions against the delayed inhibition of LTP by Aß given 7 d 
before may be due to a gradual build up of excess glutamate during the post-Aß injection. 
Previously, repeated subcutaneous (s.c.) injection of rGOT was reported to persistently 
increase the blood levels of GOT and to exert a neuroprotective effect against glutamate 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 15
excitotoxicity in an amyotrophic lateral sclerosis model (Ruban et al., 2015). Therefore in 
addition to acutely injecting blood-based glutamate scavengers i.v. on day 7, we repeatedly 
applied rGOT for 7 d (0.39 mg/rat, s.c on the day of Aß administration, day 0, followed by a 
daily maintenance dose of 0.13 mg/rat on days 1-6). In animals pre-treated with i.c.v., Aß 
followed by control vehicle systemic injections, LTP was strongly inhibited (107.1±3.7%, 
n=6; p<0.05 compared with 128.5±1.6%, n=6, in the control group, which received vehicle 
for the i.c.v., s.c. and i.v injections) (Fig. 3A, C). Importantly, repeated daily s.c. injection of 
rGOT followed on day 7 with an acute i.v. injection of rGOT (0.39 mg/rat), either with or 
without oxaloacetate (35 mg/kg), abrogated the delayed synaptic disruption by Aß given 7 d 
previously (121.5±1.6% and 129.2±3.6%, respectively, n=6 per group; p<0.05 compared with 
the Aß+vehicle group; p>0.05 compared with vehicle control group) (Fig. 3B, C). Although 
the addition of oxaloacetate on day 7 appeared to enhance the beneficial effect of GOT 
treatment, there was no significant difference between the Aß+rGOT+veh/rGOT and 
Aß+rGOT+OXA/rGOT groups (p>0.05). Moreover, the combination treatment schedule did 
not significantly affect the magnitude of control LTP (133.3±2.6%, n=5; p>0.05 compared 
with vehicle control group). 
Consistent with the electrophysiological findings, both of the effective treatment 
protocols significantly decreased serum glutamate concentration to similar extents (65.4±5.9 
and 64.1±9.7 µM, for rGOT s.c. followed by an i.v. injection of either rGOT alone or in 
combination with oxaloacetate, respectively, n=5 per group; p<0.05 compared with 
137.7±21.1 µM in samples taken from a vehicle control group, n=5) at 1 h post-i.v. injection, 
the time point when HFS was applied (Fig. 3D).  
3.3 Both acute and repeated metabotropic glutamate 5 receptor antagonist treatment 
reverses synthetic Aß-mediated persistent disruption of synaptic plasticity  
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The efficacy of repeated treatment with blood-based glutamate scavengers to abrogate the 
persistent inhibition of LTP by Aß is likely due to indirectly reducing excessive brain levels 
of glutamate. Therefore we hypothesized that centrally acting antagonism of mGlu5 
receptors, one of the main mediators of acute synaptic plasticity disruption by Aß, would also 
be effective in reversing the persistent inhibition of LTP. We gave the selective mGlu5 
receptor negative allosteric modulator basimglurant, which acts as a non-competitive 
antagonist of the receptor i.p. (2 mg/kg, either acutely or 3 times at 24 h interval with the last 
injection given 2 h prior to HFS). Either the acute or repeated treatment with basimglurant 
reversed the inhibition of LTP. Thus application of HFS 2 h after acute treatment triggered 
robust LTP (145.1±8.1% at 3 h post-HFS, p>0.05 compared with 89.5±18.5% in Aß pre-
injected rats, n=4 per group) (Fig. 4A,D).  Similarly, repeated injection on days 5-7 of 
basimglurant abrogated the persistent inhibition of LTP caused by i.c.v. injection of Aß 7 
days previously (120.5±4.8% n=5; p<0.05 compared with 96.7±5.0% in the Aß+vehicle 
group, n=6) (Fig. 4B,E). This repeated basimglurant treatment regime had no significant 
effect on control LTP (128.9±4.0% n=5, p>0.05 compared with 131.4±3.7% n=5 in vehicle 
control group) (Fig. 4C,F).  
3.4 Acute treatment with blood-based glutamate scavengers fail to reverse the disruption of 
synaptic plasticity in freely behaving transgenic rats modeling Alzheimer’s disease 
amyloidosis 
In order to determine if agents that lower blood glutamate levels can reverse synaptic 
plasticity deficits caused by endogenously produced human Aß, we tested their effectiveness 
in preventing LTP impairment in freely behaving rats overexpressing APP. Rats expressing 
human APP751 with Swedish and Indiana mutations (McGill-R-Thy1-APP, TG) have an 
age-dependent, Aß-mediated, impairment in LTP induction compared with age-matched WT 
littermates (Qi et al, 2014).  
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To establish if and when TG rats accumulate pathologically relevant Aβ aggregates we 
employed a variant of the highly sensitive Aβ oligomer-specific immunoassay developed to 
quantify soluble Aβ aggregates in AD brain (Yang et al., 2015). Aβ oligomers were not 
detected in any WT animals tested (n=10, age range 3 – 13 months). In contrast, at 3-13 
months of age there were significantly more TG animals with Aβ oligomer level above the 
lower limit of quantification (LLOQ, 80 pM) (11 of 28 TG rats, p<0.05 compared with WT 
rats, Fisher’s exact test). Indeed Aβ oligomers were detected in TG rats as young as 4 months 
(Fig. 5A). Whereas at 3 - 7 months of age oligomers were detectable in 7 out of 23 TG rats, at 
12 – 13 months of age 4 out of 5 TG animals had detectable amounts of Aβ oligomers. Thus 
there was a highly significant correlation between age and Aβ oligomer level of TG rats with 
readings above the LLOQ (n=17, Pearson r=0.89, p<0.05, R squared=0.79).  
By studying chronically implanted animals it was possible to carry out both cross-
sectional and longitudinal analyses of the treatments. We studied a range of ages just before 
or at the start of plaque deposition (6-10 month old). 
First we confirmed that this group of TG rats had a deficit in LTP (103.0±4.6% n=6, 
p<0.05 compared with 142.5±7.0% n=6 in WT litter mate group) (Fig. 5B, D). Next we 
examined the effect of acute treatment with the blood-based glutamate scavengers. Co-
administration (i.v.) of oxaloacetate and rGOT as a single bolus injection 1 h prior to HFS did 
not appear to affect control LTP in WT littermates (134.0±4.7% n=6, p<0.05 compared with 
pre-HFS baseline) or the LTP deficit in TG rats (112.3±6.9% n=6, p>0.05 compared with 
pre-HFS baseline, p<0.05 compared with WT) (Fig. 5 C, E).  
3.5 Repeated systemic treatment with blood-based glutamate scavengers reverse the 
disruption of synaptic plasticity in freely behaving transgenic rats modeling Alzheimer’s 
disease amyloidosis 
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In view of the ability of repeated administration of blood-based glutamate scavengers to 
abrogate the persistent inhibition of LTP by exogenous Aß, next we studied the effect of the 
same rGOT and oxaloacetate treatment schedule on the LTP deficit in amyloid precursor 
protein (APP) TG rats. Hence, repeated subcutaneous (s.c.) injection of rGOT (0.39 mg/rat 
initially, and a daily maintenance dose of 0.13 mg/rat for 7 d), was followed by an acute (i.v.) 
co-injection rGOT and oxaloacetate at 1 h prior to HFS on day 7. The ability to induce LTP 
was tracked longitudinally before, during and after treatment.  
Consistent with our hypothesis, in drug treated TG rats HFS induced robust LTP 
(130.5±2.3%, n=5, p<0.05 compared with 107.4±2.8%, n=5 in the TG rats that received 
vehicle treatment) (Fig. 6A, B). We also carried out a longitudinal analysis. As can be seen in 
Fig. 5C, D, HFS failed to induce persistent LTP when applied either just before initiating 
drug treatment or 7 days after treatment (99.2±3.1% and 109.7±7.8%, respectively, n=5; 
p>0.05). In the WT littermates, the repeated rGOT s.c. injection combined with acute 
OXA/rGOT i.v. injection did not significantly affect LTP (134.2±3.7% n=6 p>0.05 compared 
with 135.6±1.0% n=6 in the vehicle treated control group) (Fig. 6E, F). Moreover, in the 
longitudinal analysis it can be seen that the magnitude of LTP did not significantly change 
between pre-, during and post-treatment recording sessions (131.8±2.5% at 1 week post-
treatment, p>0.05 compared with 142.5±7.0% n=6 in the same animals prior to treatment, 
n=6) (Fig. 6G, H).  
3.6 Repeated systemic treatment with metabotropic glutamate 5 receptor antagonists rapidly 
reverses the disruption of synaptic plasticity in freely behaving transgenic rats modeling 
Alzheimer’s disease amyloidosis 
For comparison with the study that examined the effect of acute treatment with OXA/rGOT 
in McGill-R-Thy1-APP TG rats we tested the effect of a single injection of the mGlu5 
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receptor antagonist basimglurant on the ability to induce LTP in freely behaving animals. 
Similar to acute OXA/rGOT treatment, acute treatment with basimglurant failed to 
significantly reverse the LTP deficit in 5 month old TG rats. Thus, application of HFS 2 h 
after i.p. injection of a dose of 2 mg/kg did not induce significant LTP (99.3±2.8%, n=5, 
p>0.05 compared with 100.3±4.6% in the same animals one week prior to drug testing) (Fig. 
6A-C). Somewhat similarly, in 5 month old TG animals that were tested 16 h after a dose of 
3 mg/kg the magnitude of LTP was not significant at 3 h (102.7±3.5%, n=5, p>0.05 
compared with 108.6±5.4% in the same animals one week prior to drug testing), although it 
appeared to decay more slowly in these animals (Fig. 6D-F). 
As explained in the Methods section, because we had previously reported that 3 day 
treatment with anti-Aß interventions reversed the LTP deficit in the transgenic rat model (Qi 
et al., 2014) we also examined the effects of similar treatment with mGlu5 antagonists. 
Three-day treatment with basimglurant (2 mg/kg/day, i.p.) caused a strong but transient 
reversal of the LTP deficit in 5 month old TG rats. Thus, in the week prior to initiating drug 
treatment, application of HFS only induced a decremental potentiation (101.6±3.3% n=6 at 3 
h post-HFS, p>0.05 compared with pre-HFS baseline, paired t-test). In contrast, 2 h after the 
third daily injection of basimglurant, the same HFS protocol now triggered robust and stable 
LTP in the same animals (120.8±3.3%, n=6, p<0.05 compared with pre-HFS baseline, paired 
t-test). However, seven days after the last injection of basimglurant, the LTP deficit had 
returned since HFS now only induced a decremental potentiation (102.0±1.9%, n=6, p>0.05 
compared with pre-HFS baseline, paired t-test) (Fig 6).  
In order to determine if the rapidly reversible beneficial effects of basimglurant were a 
drug class effect not caused by the vehicle treatment we decided to compare the effects of 
corn oil with another mGlu5 receptor antagonist, CTEP (Hamilton et al., 2016; Jaeschke et 
al., 2015; Lindemann et al., 2011). Treatment of 5 month old TG rats with CTEP (2 mg/kg 
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over 3 days, i.p.) caused a rapid and transient reversal of the LTP deficit (Fig. 7). Thus, in the 
week prior to initiating drug treatment, application of HFS only induced a decremental 
potentiation (98.4±1.6% n=5 at 3 h post-HFS, p>0.05 compared with pre-HFS baseline, 
paired t-test). In contrast, 2 h after the second injection of CTEP, the same HFS protocol now 
triggered robust and stable LTP in the same animals (125.5±2.4% n=5, p<0.05 compared 
with 100.4±2.0% n=5 in corn oil vehicle control). Moreover, seven days after the last 
injection of CTEP, the LTP deficit had returned since HFS now only induced a decremental 
potentiation (100.8±1.5%, n=5, p>0.05 compared with pre-HFS baseline, paired t-test).  
3.7 An antibody that prevents Aß oligomer binding to cellular prion protein restores LTP in 
freely behaving transgenic rats modeling Alzheimer’s disease amyloidosis 
Previously, we and others reported that the acute inhibition of LTP by synthetic Aβ 
aggregates is prevented by acute pretreatment with antibodies against PrP that block, but not 
by those that do not affect, high affinity Aβ oligomer binding (Barry et al., 2011; Freir et al., 
2011; Hu et al., 2014; Klyubin et al., 2014a; Lauren et al., 2009; Nicoll et al., 2013). Here 
we employed the monoclonal antibody ICSM35 which is directed against the Aβ oligomer-
binding PrP 95-110 region (Freir et al., 2011; Khalili-Shirazi et al., 2007). In a blind study 
(Fig. 8), we found that repeated i.c.v. injections of ICSM35 (5x60 µg over 3 days), reversed 
the LTP deficit in 4.5-5 month-old freely behaving TG animals (131.0±5.6%, n=5, p<0.05, 
compared with 104.4±7.2%, in TG animals of similar age treated with an isotype control 
antibody, Bric126, n=6). Notably, full reversal of the effect of ICSM35 had not occurred by 2 
weeks after ceasing treatment. Thus HFS applied 2 weeks after injections of ICSM35 (post) 
still induced LTP in 3 of the 5 rats (Fig. 8).  
4. Discussion 
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Repeated systemic treatment with agents that reduce either excess glutamate, activation of 
mGlu5 receptors or binding to cellular PrP were effective in reversing persistent synaptic 
plasticity disruption caused by Aß oligomers. Administration of the blood-based glutamate 
scavenger rGOT alone or in combination with oxaloacetate lowered blood glutamate 
concentration and overcame the inhibition of LTP both by exogenously applied synthetic 
Aß1-42 aggregates in WT rats or endogenously generated Aß in pre-plaque transgenic rats. 
Moreover, brief repeated treatment with the mGlu5 receptor antagonists basimglurant and 
CTEP, or the PrP antibody ICSM35, exerted similar beneficial effects. Longitudinal 
monitoring of individual freely behaving transgenic rats revealed that the enhancement of 
LTP caused by these interventions is also relatively rapidly reversible. These data strongly 
indicate that the persistent impairment of LTP by either exogenous or endogenous Aß 
oligomers is mediated by excessively increased brain glutamate, inappropriate mGlu5 
receptor activation and Aß oligomer binding to cellular PrP.   In addition, the findings are 
potentially relevant to the development of clinical interventions designed to reverse synaptic 
deficits in patients with early Alzheimer’s disease. 
Blood-based glutamate scavengers offer a novel means of promoting brain glutamate 
homeostasis. The prediction, based on our previous studies on the abrogation of the acute 
inhibition of LTP by soluble synthetic or Alzheimer’s disease brain Aß (Zhang et al., 2016), 
that acute treatment with the blood-based scavengers would ameliorate the persistent 
disruption of LTP by Aß was not supported. However, supplementation of the acute 
injections with repeated systemic treatment of rGOT was very effective in reversing the 
persistent inhibition of LTP caused by either exogenous or endogenous Aß exposure. 
Physiological homeostasis of glutamate concentration in the body is promoted by the blood 
resident enzyme GOT, which converts glutamate to α-ketoglutarate in the presence of 
oxaloacetate (Campos et al., 2011b; Castillo et al., 2016; Zlotnik et al., 2007). In the present 
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experiments this system was supplemented by systemic injection of both oxaloacetate and 
rGOT, neither of which cross the blood brain barrier to any significant extent (Boyko et al., 
2012; Hassel et al., 2002). Blood-based glutamate scavengers preferentially promote excess 
glutamate clearance from the brain by increasing the concentration gradient between the 
blood and luminal side of endothelial cells in cerebral blood vessels, which in turn promotes 
removal of any excess glutamate in the brain’s interstitial fluid (Castillo et al., 2016; Cohen-
Kashi-Malina et al., 2012; Gottlieb et al., 2003; Ruban et al., 2015). The effects of 
oxaloacetate and rGOT on brain glutamate concentration should be selective for excessive 
levels, with minimal effects on physiological levels. This is because under physiological 
conditions glutamate is cleared primarily by neuronal and glial transporters and therefore 
would not reach sufficient levels to activate transporters on the abluminal side of the 
endothelial cells (Castillo et al., 2016; Gottlieb et al., 2003; Zlotnik et al., 2007). In the 
present studies it is unclear whether or not the success of supplementation with daily s.c. 
rGOT treatments was principally due to a boosting of the brain glutamate lowering effect of 
the acute i.v. injections or also because prolonged blood-based glutamate scavenging by 
rGOT is necessary to prevent persistent downstream deleterious effects of elevated brain 
glutamate concentration that mediate Aß-induced inhibition of LTP.  
The ability of repeated systemic treatment with an mGlu5 receptor antagonist to mimic 
the ameliorative effect of the blood-based glutamate scavengers in the two chronic Aß 
models lends support to the critical role of inappropriate glutamate receptor activation in 
mediating the persistent inhibition of LTP by exogenous and endogenous Aß. These data 
extend previous studies on the efficacy of acute treatment with mGlu5 receptor antagonists 
on synaptic plasticity disruption by acute Aß (Hu et al., 2014; Jaeschke et al., 2015; 
Lindemann et al., 2015; Rammes et al., 2011) and are consistent with reports that repeated 
administration of these agents in APP transgenic mice ameliorates deficits in the performance 
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of learning tasks (Hamilton et al., 2016; Um et al., 2013). In addition to blocking over-
activation of these receptors that has been triggered by excessive extracellular glutamate 
levels, selective antagonists can also prevent mGlu5 receptors being inappropriately activated 
by Aß-bound PrP, which, in conjunction with mGlu5, is a major extracellular toxic receptor 
for certain Aß oligomers (Beraldo et al., 2016; Haas et al., 2016; Hamilton et al., 2015; 
Lauren et al., 2009; Um et al., 2013). Hence, we examined the action of ICSM35, an antibody 
that prevents Aß oligomer binding to residues 95-110 of cellular PrP, and found that it was as 
effective as the mGlu5 receptor antagonists when administered repeatedly over a similar 
period of 3 days. This time frame is consistent with our previous finding that 3-day treatment 
with agents that either lower or bind Aß was sufficient to abrogate the impairment of LTP in 
the transgenic rat model (Qi et al., 2014). The finding of age-dependent accumulation of Aß 
oligomers in the brains of these rats supports previous observations of the presence of Aß 
oligomers intracellularly (Iulita et al., 2014; Leon et al., 2010). The levels we detected in 
younger rats were near the LLOQ, consistent with our previous research which failed to 
detect Aß oligomers using less sensitive Western blotting techniques (Qi et al., 2014). 
Despite the relatively low levels of detectable oligomers in the brains of younger rats, the 
ability of ICSM35 to reverse the LTP deficit strongly indicates that sufficient amounts are 
present extracellularly to bind PrP, which is an extracellular receptor for synaptotoxic Aß 
aggregates.  
Some differences emerged between the acute effect of the different treatments in the two 
Aß models. Thus, acute basimglurant was effective in reversing the disruption of synaptic 
plasticity by injection of synthetic Aß 7 days previously, whereas a single administration of 
basimglurant either 2 or 16 h prior to HFS failed to reinstate LTP induction in the transgenic 
rats. On the other hand acute OXA/rGOT failed to reverse the LTP deficit in either the 
delayed Aß model or the transgenic rats. In the case of the persistent inhibition of LTP by 
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exogenous Aß, it seems likely that the deleterious effect is due to continued presence of the 
injected ADDL oligomers in the brain. It is known that Aß concentration remains elevated for 
at least 7 d after i.c.v. injection of ADDLs  (Figueiredo et al., 2013; Zhang et al., 2014) and 
we found that injection of an anti-Aß antibody 2 h prior to HFS on day 7 completely reversed 
the LTP deficit (Ondrejcak et al., 2016). It seems unlikely that major structural changes 
mediate the disruption of LTP since baseline synaptic transmission and short-term plasticity 
were not significantly impaired on day 7 and the ability to induce LTP had recovered by day 
14. Nevertheless we cannot rule out the possibility that a synaptotoxic conformation of Aß is 
stabilized in vivo or that structural changes accompany the functional deficit. In the case of 
the impairment of LTP in the transgenic animals something between 16 h and 3 days after 
initiating basimglurant treatment was required for full recovery. This could be taken to imply 
that structural changes may mediate the disruption of plasticity, though again, we failed to 
detect interference with baseline AMPA receptor-mediated synaptic transmission or short-
term plasticity in the transgenic rats at 5-6 months of age (Qi et al., 2014). Consistent with 
these findings, Martino Adami et al (2017) reported that hippocampal CA1 structural 
integrity, as measured by synaptic density using electron microscopy or PSD-95 using 
western blots, is normal at 6 months. However, at 5-6 months of age both CA1 synaptic 
mitochondrial bioenergetics (Martino Adami et al., 2017) and NMDA receptor-mediated 
transmission (Qi et al., 2014) are reduced. Future studies should examine the possibility that 
the time course of recovery triggered by basimglurant corresponds to the time needed to 
restore normal synaptic bioenergetics, distribution of NMDA receptors or possibly synaptic 
structure. 
By carrying out longitudinal studies, in addition to the direct comparison with control 
treatment groups, it was possible to track the time-course of reversal of the beneficial effects 
of the interventions in individual TG rats. In most groups the treatment effect had fully 
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reversed within one week of ceasing treatment, similar to the anti-Aß strategies investigated 
previously in this rat model using an anti-Aß antibody or secretase inhibitors (Qi et al., 2014). 
However, the rate of reversal of the beneficial effect of the anti-PrP antibody appeared to be 
somewhat slower than that present in animals treated with either the mGlu5 receptor 
antagonists or the blood-based glutamate scavengers. We have no explanation for this 
apparent difference. 
Many different Aß cellular mechanisms have been reported to mediate Aß-induced 
increases in extracellular brain glutamate levels and synaptic plasticity disruption (Viola and 
Klein, 2015; Zadori et al., 2014). Currently it is unknown if Aß-induced increases in 
extracellular glutamate concentration are at least partly mediated by binding to cellular PrP. 
Since activation of the PrP co-receptor mGlu5 receptors on astrocytes can trigger non-
vesicular glutamate release (Angulo et al., 2004; D'Ascenzo et al., 2007; Fellin et al., 2004) it 
is possible that Aß binding to PrP on astrocytes may increase glutamate release. Interestingly 
mGlu5 receptor triggered glutamate release from astrocytes appears to preferentially access 
extrasynaptic GluN2B-containing NMDA receptors (Angulo et al., 2004; D'Ascenzo et al., 
2007; Fellin et al., 2004), and these receptors have been strongly implicated in mediating the 
acute inhibition of LTP by Aß oligomers (Hu et al., 2008; Li et al., 2009). Moreover, Aß 
oligomer-induced glutamate release from astrocytes has been reported to increase 
extrasynaptic NMDA receptor activation that may contribute to synaptic damage (Talantova 
et al., 2013).  
Consistent with our findings from previous studies of acute i.v. treatment with 
oxaloacetate alone or in combination with rGOT in anaesthetized rats (Zhang et al., 2016) we 
now report that repeated administration of rGOT combined with acute i.v. treatment with 
these agents also did not to disrupt control LTP in either anaesthetized or awake freely 
behaving animals. The lack of detectible deleterious effects of repeated treatment with these 
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blood-based glutamate scavengers on control LTP presumably reflects, as discussed above, 
their relative selective ability to reduce excessive, non-physiological, levels of brain 
glutamate (Castillo et al., 2016). The lack of significant effect on LTP in control animals 
indicates that potentially there is a beneficial dose range of the agents against Aß that does 
not disrupt physiological plasticity. Further study will be required to rule out the possibility 
that other synaptic functions and plasticity induced by different protocols in other pathways 
are not affected by repeated treatment with blood-based glutamate scavengers. Significantly, 
the blood concentration of endogenous GOT correlates positively with stroke outcome and is 
known to reach relatively high levels in healthy humans (Campos et al., 2011a; Castillo et al., 
2016; Tian et al., 2012). 
Similarly, the repeated dosing schedule for the mGlu5 receptor antagonists used here did 
not affect control LTP at 3 h post-HFS. However, it seems probable that later time points or 
other forms of plasticity may be impeded in the dose range that ameliorated the detrimental 
effects of Aß. Extensive research has shown that certain forms of LTP, LTD and 
depotentiation are inhibited by these agents in brain areas including the hippocampus under 
physiological conditions (Anwyl, 2009; Buschler and Manahan-Vaughan, 2016; Collingridge 
et al., 2010; Qi et al., 2013; Zarnadze et al., 2016) . Indeed, mGlu5 receptor activation can 
“reinforce” the induction of longer-lasting forms of LTP, and late-phase LTP may be more 
sensitive than early phase LTP to block of group I receptors (Balschun et al., 1999; Manahan-
Vaughan, 1997). Somewhat similarly, behavioral effects of blocking these receptors in 
animals appear to be relatively task specific (Ahnaou et al., 2015). Indeed, doses of mGlu5 
receptor antagonists that were effective in attenuating behavioural deficits in APP transgenic 
mouse models also slightly interfered with performance in non-TG mice (Hamilton et al., 
2014; Um et al., 2013). Thus on the one hand, there is a generally accepted view that ongoing 
activation of mGlu5 receptors is likely to be necessary for normal cognitive function and 
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underlying plasticity mechanisms. On the other hand, in clinical trials of antagonists, 
including basimglurant, at potentially therapeutic doses, dizziness and visual hallucinations 
rather than cognitive impairment have been found to be dose-limiting in humans (Berry-
Kravis et al., 2016; Reilmann et al., 2015; Scharf et al., 2015; Tison et al., 2016). 
Further pre-clinical studies of rGOT treatment that extend our present findings will be 
required to determine if such an approach may prove promising as a potential therapeutic in 
very early stages of the disease. In the case of mGlu5 receptor antagonists that have already 
been used safely in human studies the current evidence indicates that adverse effects may not 
markedly limit their potential benefits. A similar case can be made for antibodies preventing 
Aß oligomer binding to PrP, although to date they have only been tested in preclinical models 
(Klyubin et al., 2014a). Certainly, a strategy of targeting both glutamate clearance and mGlu5 
receptors/PrP mechanisms warrants further investigation to determine if such a dual approach 
can limit potential adverse effects while maintaining efficacy. 
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Fig. 1. A single injection of ADDLs persistently inhibits LTP in the CA1 area of the rat 
hippocampus in vivo. (A) In control animals, that were injected i.c.v. with vehicle (Veh) 
under recovery anaesthesia and recorded from 7-14 d later under non-recovery anaesthesia, 
the application of HFS (arrow) induced robust LTP that lasted at least 3 h (p<0.05 compared 
with pre-HFS baseline, paired t-test). In contrast, in animals injected 7-9 days previously with 
an ADDL preparation of Aß1-42 enriched in protofibrils (Aß7, 480 pmol, i.c.v.), a 
decremental LTP was induced (p>0.05 compared with pre-HFS baseline at 3h post-HFS). 
Interestingly, the inhibition of LTP by Aß was no longer detectible 14 d after the injection 
(Aß14). Insets show representative EPSP traces at the times indicated. alibration bars: 
Vertical, 1.0 mV; horizontal, 10 ms. (B) Summary bar chart comparing the magnitude of 
synaptic potentiation between treatment groups at 3 h post-HFS. Values are the mean ± SEM 
fEPSP amplitude expressed as a percentage of the pre-HFS baseline. (C, D) Lack of change 
in either (C) the input/output relationship as measured by the magnitude of the response to 
different intensities of stimulation (50, 75 and 100% maximum) or (D) short term plasticity 
as measured by the magnitude of the paired-pulse facilitation ratio at a 40 ms inter pulse 
interval.  *p<0.05, one-way ANOVA followed by Bonferroni test. 
Fig. 2. Acute systemic treatment with the blood-based glutamate scavenger oxaloacetate 
alone or in combination with recombinant glutamate oxaloacetate transaminase failed to 
reverse synthetic Aß-mediated persistent inhibition of LTP. (A) In control animals, that were 
injected i.c.v. with vehicle for Aß and seven days later injected i.v. (‘plus’ symbol) with 
vehicle for oxaloacetate (Veh+Veh), the application of 3 sets of HFS (3 arrows) induced 
robust LTP that was relatively stable for at least 3 h (p<0.05 compared with pre-HFS 
baseline, paired t-test). In contrast, in animals injected with an ADDL preparation of Aß1-42 
enriched in protofibrils (Aß, i.c.v.) 7 days before i.v. vehicle (Aß+Veh), a decremental LTP 
was induced by the same HFS  protocol (p>0.05 compared with pre-HFS baseline at 3h post-
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HFS). (B) In animals that received oxaloacetate i.v. (plus symbol, 35 mg/kg in 1 ml) 1 h prior 
to HFS (arrows) on day 7 post-Aß administration, the application of HFS failed to induce 
stable LTP (Aß+OXA) (p>0.05 compared with pre-HFS baseline at 3 h post-HFS and 
Aß+Veh group). (C) We tested the effect of a dose (0.39 mg/rat i.v.) of recombinant type 1 
GOT (rGOT) that when administered alone did not prevent the inhibition of LTP by Aß 
(rGOT/Veh+Aß) (p>0.05 compared with pre-HFS baseline at 3 h post-HFS), together with 
oxaloacetate (rGOT/OXA+Aß). However, no significant beneficial effect was observed 
(p>0.05 compared with pre-HFS baseline at 3 h post-HFS). (D, E) Summary bar chart 
comparing the magnitude of synaptic potentiation between treatment groups at 3 h post-HFS. 
Values are the mean ± SEM fEPSP amplitude expressed as a percentage of the pre-HFS 
baseline. *p<0.05, unpaired t-test or one-way ANOVA followed by Bonferroni test. 
Fig. 3. Repeated treatment with rGOT alone or in combination with acute treatment of 
oxaloacetate reverses synthetic Aß-mediated persistent inhibition of LTP. (A) HFS (arrows) 
induced robust LTP in control animals that received vehicle injections (i.c.v. on day 0; 0.2 
ml/day, s.c. on days 0-6; and 1 ml i.v. on the day of recording, plus symbol) (Veh+Veh+Veh) 
(p<0.05 compared with pre-HFS baseline). In contrast, LTP was inhibited seven days after 
i.c.v. injection of Aß (Aß+Veh+Veh) (p>0.05 compared with pre-HFS baseline, p<0.05 
compared with Veh+Veh+Veh group). (B) In Aß pre-treated rats followed by repeated rGOT 
alone (s.c. + i.v.) (Aß+rGOT+Veh/rGOT), or in combination with oxaloacetate on day 7 
(Aß+rGOT+OXA/rGOT), application of HFS induced LTP that was indistinguishable from 
vehicle control group (p>0.05 compared with Veh+Veh+Veh group, p<0.05 compared with 
Aß+Veh+Veh group). (C) Summary bar chart comparing the magnitude of synaptic 
potentiation at 3 h post-HFS between treatment groups. Values are the mean ± SEM fEPSP 
amplitude expressed as a percentage of the pre-HFS baseline. (D) Compared with vehicle 
control group, the serum glutamate levels were significantly reduced in both 
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Aß+rGOT+Veh/rGOT (n=5) and Aß+rGOT+OXA/rGOT (n=5) groups. *p<0.05, one-way 
ANOVA followed by Bonferroni test. 
Fig. 4. Both acute and repeated treatment with the mGlu5 receptor antagonist basimglurant 
abrogates synthetic Aß-mediated persistent inhibition of LTP. (A) Whereas LTP was 
inhibited in Aß (i.c.v.) pre-injected animals, in rats given basimglurant (2 mg/kg i.p., single 
injection) (Aß+BMG) HFS now induced a robust LTP (p<0.05 compared with pre-HFS 
baseline, paired t-test). (B) Similarly, in rats given basimglurant (3 daily injections of 2 
mg/kg i.p.) (Aß+BMG) the application of HFS 2 h after the last injection induced robust LTP 
(p<0.05). (C) In control rats that received vehicle (0.3ml, once a day for 3 days) (Veh), the 
application of HFS, 2 h after the last injection, induced robust LTP that was relatively stable 
for at least 3 h (p<0.05). HFS induced similar LTP in animals treated with basimglurant (2 
mg/kg/day for 3 days) in the same manner (p<0.05). (D-F) Summary bar charts comparing 
the magnitude of synaptic potentiation at 3 h post-HFS between treatment groups. Values are 
the mean ± SEM fEPSP amplitude expressed as a percentage of the pre-HFS baseline. 
*p<0.05, unpaired t-test. 
Fig. 5. Acute co-treatment with the blood-based glutamate scavengers oxaloacetate and 
rGOT fails to reverse the inhibition of LTP in freely behaving APP over-expressing 
transgenic rats. (A) An oligomer-specific DELFIA reveals an age-dependent accumulation of 
Aβ assemblies in the brain of McGill-R-Thy1-APP TG rats. Soluble extracts of rat brains 
were assayed by DELFIA using the anti-Aβ oligomer selective monoclonal antibody 1C22. 
The lower limit of quantification (LLOQ, dotted line) was 80 pM. Oligomers were detected 
in 11 of 28 TG rats aged 3-13 months but in none of the 10 WT littermates of a similar age 
range. Values are the mean±SD for each rat. (B) A single set of HFS (arrow) failed to induce 
LTP in APP TG animals (TG) (p>0.05 compared with pre-HFS baseline), while this HFS 
protocol induced robust LTP in WT littermates (WT) (p<0.05 compared with pre-HFS 
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baseline, p<0.05 compared with TG rats). (C) In TG animals that received oxaloacetate and 
rGOT (35mg/kg and 0.39mg/rat respectively, i.v.), application of HFS 1 h later failed to 
induce LTP (p>0.05 compared with pre-HFS baseline). This treatment did not appear to 
affect control LTP in WT littermates (p<0.05 compared with pre-HFS baseline, p<0.05 
compared with TG rats). (D,E) Summary bar chart comparing the magnitude of synaptic 
potentiation at 3 h post-HFS between treatment groups. Values are the mean ± SEM fEPSP 
amplitude expressed as a percentage of the pre-HFS baseline. *p<0.05, unpaired t-test. 
Fig. 6. Repeated treatment of rGOT combined with acute treatment of rGOT and 
oxaloacetate reverse the LTP deficit in APP TG rats. (A) In TG rats, HFS (arrow) failed to 
induce robust LTP in animals that received repeated s.c. (0.2 ml/day, not illustrated) and i.v. 
(1 ml, not illustrated) injection of proper vehicle (Veh+Veh) (p>0.05 compared with pre-HFS 
baseline). Repeated s.c. injection of rGOT (0.39 mg/rat) combined with oxaloacetate (35 
mg/kg, i.v.) and rGOT (0.39 mg/rat, i.v.) pre-treated 1 h prior to HFS, LTP was reversed 
(rGOT+rGOT/OXA) (p<0.05 compared with pre-HFS baseline, p<0.05 compared with 
Veh+Veh group). (B) Summary bar chart comparing the magnitude of synaptic potentiation 
at 3 h post-HFS between treatment groups in (A). (C, D) The recovery from the impairment 
in synaptic plasticity lasted for less than a week in the drug-treated group. The same HFS 
protocol applied either just before (pre) or one week after (post) the injections of drugs failed 
to induce LTP. Data for individual animals are shown in (C) and summarized statistically in 
the bar charts (D). (E) In WT litter mates of Tg animals, either vehicle (Veh+Veh) or drug 
(rGOT+rGOT/OXA) treatments have significant effect on LTP (p<0.05 compared with pre-
HFS baseline, p>0.05 compared with Veh+Veh group). (F) Summary bar chart comparing 
the magnitude of synaptic potentiation at 3 h post-HFS between treatment groups in (E). (G, 
H) The same HFS protocol applied either just before (pre) or one week after (post) the 
injections of drugs n=6 induced LTP that have no significant difference. Data for individual 
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animals are shown in (G) and summarized statistically in the bar charts (H). Values are the 
mean ± SEM fEPSP amplitude expressed as a percentage of the pre-HFS baseline. *p<0.05, 
unpaired t-test or one-way ANOVA followed by Bonferroni test. 
Fig. 7. Acute treatment with the mGlu5 receptor antagonist basimglurant failed to reverse the 
LTP deficit in APP TG rats. (A) In TG rats HFS failed to induce LTP 2 h after being treated 
with basimglurant (BMG, n=5, 2 mg/kg, i.p.), similar to 7 days before treatment (Pre). (D) 
Similarly, HFS failed to induce LTP 16 h after being treated with basimglurant (BMG, n=5, 3 
mg/kg, i.p.). Magnitude of LTP (B,E) measured 3 h post-HFS tracked in individual rats or 
(C,F) summarized statistically in a bar chart. Values are the mean ± S.E.M. % pre-HFS 
baseline EPSP amplitude.  
Fig. 8. Repeated treatment with the mGlu5 receptor antagonist basimglurant transiently 
reversed the LTP deficit in APP TG rats. (A) In TG rats HFS triggered robust and stable LTP 
while being treated with basimglurant (n=6, 2 mg/kg/day for 3 days, i.p.) but not before (pre) 
or 7 days after (post) treatment. (B) Magnitude of LTP measured 3 h post-HFS tracked in 
individual rats (B) or summarized statistically in the bar chart (C). *p<0.05 compared with 
pretreatment levels of potentiation in the same animals. Values are the mean ± S.E.M. % pre-
HFS baseline EPSP amplitude. *p<0.05, one-way ANOVA followed by Bonferroni test. 
Fig. 9. Repeated treatment with the mGlu5 receptor antagonist CTEP transiently reversed the 
LTP deficit in APP TG rats. (A) In TG rats that received vehicle (0.3 ml, twice over 3 days) 
(Veh), the application of HFS, 2 h after the last injection, failed to induce robust LTP (p>0.05 
compared with pre-HFS baseline, paired t-test). However, HFS induced robust LTP that was 
relatively stable for at least 3 h in animals treated with CTEP (2 mg/kg, twice in 3 days) 
(p<0.05 compared with Veh). (B) Summary bar chart comparing the magnitude of synaptic 
potentiation at 3 h post-HFS between treatment groups in (A). (C, D) The recovery from the 
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impairment in synaptic plasticity lasted for less than a week in the drug-treated group. The 
same HFS protocol applied either just before (pre) or one week after (post) the injections of 
drugs failed to induce LTP. Data for individual animals are shown in (C) and summarized 
statistically in the bar charts (D). *p<0.05, unpaired t-test or one-way ANOVA followed by 
Bonferroni test. 
Fig. 10. Repeated treatment with an antibody that blocks Aß oligomer binding to cellular 
prion protein, ICSM35, transiently reversed the LTP deficit in APP TG rats. (A) Three-day 
treatment with ICSM35 (5 X 60 µg injections over 3 days, i.c.v.) transiently restored the 
ability to induce LTP in TG rats. In animals treated with ICSM35, but not with an isotype 
control IgG antibody BRIC126, HFS triggered robust LTP. Insets show representative EPSP 
traces at the times indicated. Calibration bars: Vertical, 1.0 mV; horizontal, 10 ms. (B) 
Summary bar chart of the magnitude of synaptic potentiation at 3 h post-HFS. *p<0.05, 
unpaired t-test. (C) Data for individual animals are shown for before (pre), during and 2 
weeks after ICSM35. Data from C summarized statistically in bar charts. *P<0.05 compared 
with pre. Values are the mean ± S.E.M. % pre-HFS baseline EPSP amplitude. *p<0.05, one-
way ANOVA followed by Bonferroni test. 
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Highlights 
A blood-based glutamate scavenger reverses the persistent disruption of synaptic plasticity by Aß oligomers 
An mGlu5R antagonist or antibody that prevents Aß oligomer binding to PrP, act similarly 
Longitudinal studies in freely behaving transgenic rats reveal the rapid time-course  
